Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFICA phase 3 trial of pacritinib versus physician's choice in myelofibrosis with severe thrombocytopenia
2017-001772-28Phase 3Unknown
- Sponsor
- CTI BioPharma Corp.
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pacritinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF) (2 arms), sponsored by CTI BioPharma Corp. Primary endpoint: Spleen volume reduction response. Status: unknown.
02
Drugs
pacritinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2017-001772-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001772-28.